BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...Inc. said Ken Horne would become president, COO and board member. He was CEO of Symic Bio...
BioCentury | Apr 20, 2018
Clinical News

Symic's SB-061 misses in Phase II for OA of the knee

...In February, Symic Bio Inc. (Emeryville, Calif.) reported top-line data from the Phase II MODIFY2 trial in 60...
...patients with knee effusions this year. The candidate is a mimic of the proteoglycan aggrecan. Symic Bio Inc....
...Rating Scale (NRS) of pain Status: Phase II data Milestone: Start Phase IIb (2018) Claire Quang SB061, SB-061 Symic Bio Inc....
BioCentury | Apr 20, 2018
Clinical News

Symic reports Phase I/II data for SB-030 in peripheral vascular disease

...proteoglycan decorin, which binds to collagen that is exposed when the vascular endothelium is denuded. Symic Bio Inc....
...lumen loss at six months Status: Phase I/II data Milestone: Start Phase II (2H18) Sandi Wong SB-030, sbcv-030 Symic Bio Inc. collagen...
BioCentury | Jan 24, 2018
Company News

Management tracks: Gritstone, Disarm, Symic

...of the Center for External Innovation at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Matrix biology company Symic Bio Inc....
BioCentury | Nov 3, 2017
Company News

Management tracks: Tissue Regenix, Therapix

...director of the Canada unit at Merck & Co. Inc. (NYSE:MRK). Extracellular matrix biology company Symic Bio Inc....
BioCentury | Jul 15, 2017
Company News

Management tracks

...serving as COO of Cardeas Pharma Corp. (Seattle, Wash.) from 2011-16. Extracellular matrix biology company Symic Bio Inc....
...is a professor of medicinal chemistry at the University of Utah , and was on Symic Bio’s...
BioCentury | May 26, 2017
Financial News

Symic Bio raises $30M in series B

...On May 22, matrix biology company Symic Bio Inc. (Emeryville, Calif.) raised $30 million in a series B...
...Ventures and Alexandria Real Estate Equities. Other undisclosed investors also participated. Symic Bio Inc. , Emeryville, Calif. Chris Lieu Symic Bio Inc....
BioCentury | May 23, 2017
Financial News

Symic Bio raises $30M in series B

...Matrix biology company Symic Bio Inc. (Emeryville, Calif.) raised $30 million in a series B round from new...
...decorin , which binds to collagen that is exposed when the vascular endothelium is denuded. Symic Bio...
...a mimic of the proteoglycan aggrecan , to treat osteoarthritis (OA) of the knee. Chris Lieu SB-030 SB-061 Symic Bio Inc. Collagen...
BioCentury | Nov 17, 2016
Clinical News

SB-061: Completed Ph I/IIa enrollment

...year, Symic and Nordic partnered to develop Symic's SB-061. Nordic Bioscience A/S , Herlev, Denmark Symic Bio Inc....
...NRS) of pain Status: Completed Phase I/IIa enrollment Milestone: Phase I/IIa data (1H17) Alex Himes SB-061 Nordic Bioscience A/S Symic Bio Inc....
BioCentury | Aug 15, 2016
Finance

Serving returns

...triglycerides. While Ally Bridge's bets in AD and diabetes focus on single assets, portfolio company Symic Biomedical...
...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Servier, Neuilly-sur-Seine, France Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Symic Biomedical...
...Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) PRS-080, a first-in-class anticalin hepcidin antagonist to treat anemia Ph I Symic Biomedical...
Items per page:
1 - 10 of 20
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...Inc. said Ken Horne would become president, COO and board member. He was CEO of Symic Bio...
BioCentury | Apr 20, 2018
Clinical News

Symic's SB-061 misses in Phase II for OA of the knee

...In February, Symic Bio Inc. (Emeryville, Calif.) reported top-line data from the Phase II MODIFY2 trial in 60...
...patients with knee effusions this year. The candidate is a mimic of the proteoglycan aggrecan. Symic Bio Inc....
...Rating Scale (NRS) of pain Status: Phase II data Milestone: Start Phase IIb (2018) Claire Quang SB061, SB-061 Symic Bio Inc....
BioCentury | Apr 20, 2018
Clinical News

Symic reports Phase I/II data for SB-030 in peripheral vascular disease

...proteoglycan decorin, which binds to collagen that is exposed when the vascular endothelium is denuded. Symic Bio Inc....
...lumen loss at six months Status: Phase I/II data Milestone: Start Phase II (2H18) Sandi Wong SB-030, sbcv-030 Symic Bio Inc. collagen...
BioCentury | Jan 24, 2018
Company News

Management tracks: Gritstone, Disarm, Symic

...of the Center for External Innovation at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). Matrix biology company Symic Bio Inc....
BioCentury | Nov 3, 2017
Company News

Management tracks: Tissue Regenix, Therapix

...director of the Canada unit at Merck & Co. Inc. (NYSE:MRK). Extracellular matrix biology company Symic Bio Inc....
BioCentury | Jul 15, 2017
Company News

Management tracks

...serving as COO of Cardeas Pharma Corp. (Seattle, Wash.) from 2011-16. Extracellular matrix biology company Symic Bio Inc....
...is a professor of medicinal chemistry at the University of Utah , and was on Symic Bio’s...
BioCentury | May 26, 2017
Financial News

Symic Bio raises $30M in series B

...On May 22, matrix biology company Symic Bio Inc. (Emeryville, Calif.) raised $30 million in a series B...
...Ventures and Alexandria Real Estate Equities. Other undisclosed investors also participated. Symic Bio Inc. , Emeryville, Calif. Chris Lieu Symic Bio Inc....
BioCentury | May 23, 2017
Financial News

Symic Bio raises $30M in series B

...Matrix biology company Symic Bio Inc. (Emeryville, Calif.) raised $30 million in a series B round from new...
...decorin , which binds to collagen that is exposed when the vascular endothelium is denuded. Symic Bio...
...a mimic of the proteoglycan aggrecan , to treat osteoarthritis (OA) of the knee. Chris Lieu SB-030 SB-061 Symic Bio Inc. Collagen...
BioCentury | Nov 17, 2016
Clinical News

SB-061: Completed Ph I/IIa enrollment

...year, Symic and Nordic partnered to develop Symic's SB-061. Nordic Bioscience A/S , Herlev, Denmark Symic Bio Inc....
...NRS) of pain Status: Completed Phase I/IIa enrollment Milestone: Phase I/IIa data (1H17) Alex Himes SB-061 Nordic Bioscience A/S Symic Bio Inc....
BioCentury | Aug 15, 2016
Finance

Serving returns

...triglycerides. While Ally Bridge's bets in AD and diabetes focus on single assets, portfolio company Symic Biomedical...
...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Servier, Neuilly-sur-Seine, France Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Symic Biomedical...
...Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) PRS-080, a first-in-class anticalin hepcidin antagonist to treat anemia Ph I Symic Biomedical...
Items per page:
1 - 10 of 20